Cynata Therapeutics Completes Enrollment in Phase 2 Trial of CYP-001 for Acute Graft-Versus-Host Disease
核心洞察
Cynata Therapeutics (搜索) has completed patient enrollment in its Phase 2 clinical trial of CYP-001, enrolling 65 participants across the US, Europe, and Australia with newly diagnosed acute graft-versus-host disease.
The randomized, placebo-controlled trial will evaluate CYP-001 plus steroids versus steroids plus placebo, with primary results expected in June 2026 following a 100-day evaluation period.
CYP-001 demonstrated promising Phase 1 results in steroid-resistant aGvHD patients, showing 87% overall response rate and 60% two-year survival rate.
Cynata Therapeutics (搜索) Limited has completed patient enrollment in its Phase 2 clinical trial evaluating CYP-001 for the treatment of acute graft-versus-host disease (aGvHD), marking a significant milestone for the Australian biotechnology company's lead cell therapy candidate. The randomized, placebo-controlled study enrolled 65 participants across clinical centers in the United States, Europe, and Australia.
Trial Design and Timeline
The Phase 2 trial is evaluating CYP-001 in adults with newly diagnosed, high-risk acute graft-versus-host disease. Each participant was randomized to receive either steroids plus CYP-001 or steroids plus placebo. The study features a 100-day primary evaluation period, with the primary endpoint being Overall Response Rate at Day 28.
The primary evaluation period is expected to conclude in March 2026, with results anticipated around June 2026. Dr. Kilian Kelly, Cynata's Chief Executive Officer and Managing Director, expressed optimism about the trial's potential impact on patients with this debilitating condition.
Addressing Critical Medical Need
Acute graft-versus-host disease represents a serious and often life-threatening complication of bone marrow transplantation, affecting up to 50% of patients who receive transplants from other donors. The condition occurs when donor immune cells attack the recipient's tissues. Standard first-line treatment with steroids fails in approximately half of all aGvHD cases, creating steroid-resistant cases with historically poor outcomes.
Historical two-year survival rates in patients with steroid-resistant aGvHD are less than 20%, highlighting the urgent need for more effective therapeutic options. Kelly noted that existing treatments often fail to prevent poor outcomes while potentially causing serious safety concerns.
Promising Phase 1 Results
CYP-001, Cynata's Cymerus™ iPSC-derived mesenchymal stem cell product for intravenous use, is designed to modulate the immune system and improve both response rates and survival outcomes in aGvHD. The therapy demonstrated encouraging results in a Phase 1 trial in patients with steroid-resistant aGvHD.
In the Phase 1 study, 87% of patients showed an Overall Response, while 53% demonstrated a Complete Response. Notably, 60% of patients survived for at least two years. The trial reported no serious adverse events or safety concerns related to CYP-001 treatment. These groundbreaking results led to two publications in the prestigious journal Nature Medicine.
Regulatory Recognition and Technology Platform
CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of aGvHD, qualifying Cynata for incentives including extended marketing exclusivity, tax credits, and fee waivers.
The therapy is based on Cynata's proprietary Cymerus™ therapeutic stem cell platform technology, which uses induced pluripotent stem cells to achieve economic manufacture of cell therapy products at commercial scale. This approach overcomes challenges associated with conventional mesenchymal stem cell production by eliminating the need to obtain tissue from multiple donors on an ongoing basis.
Broader Clinical Pipeline
Beyond the aGvHD program, Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates in multiple indications. The company is conducting additional clinical trials, including a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation and a Phase 3 trial of CYP-004 in osteoarthritis.
The company has also demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome, and cytokine release syndrome.